Excellence at the point of care
We are committed to helping pioneer a new era in diagnostic technology, where the results from DNA and RNA-based tests can be obtained in the moment of need, at the point of care.
Founded in 2010 by Rustem Ismagilov and Brian Coe with a vision to bring the full power of a lab to the point of care, Talis has evolved from a two-person, university and grant funded research initiative to the public company we are today.
TEST TO TREAT
To keep life moving forward, even as new variants may continue to emerge, COVID-19 testing remains important to ensure appropriate patient management and supports the government’s Test to Treat initiative.
Learn More
A PRESSING PUBLIC HEALTH CHALLENGE
At Talis, we are pioneering science and technology to diagnose infectious disease rapidly, accurately, and directly at the point of care. Fueled by excellence and clinical rigor, we’re developing a robust menu of tests for women’s and sexual health.
Contact Us
One system, multiple applications
With access to lab-quality molecular diagnostics at the point of need, clinicians get timely results for actionable decision making. In the future, our portfolio of point-of-care diagnostic tests will include solutions for multiple infectious disease states in a variety of settings.
Learn More
TALIS BIOMEDICAL
The GenBody COVID-19 Ag Test is for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.
†The Talis One Test System is not authorized, cleared, or approved by the FDA and is not available for sale.
© Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.
* Testing solutions are currently in development and not available for sale.